My watch list
my.bionity.com  
Login  

Forest Laboratories



Forest Laboratories is a pharmaceutical company headquartered in New York City, USA. Its revenues for the year ended 31 March 2007 were US$3.4 billion. The company's research & development spending has grown rapidly in recent years and as of 2007 its R&D spending, almost a billion US dollars a year, put it on the list of the global top 100 corporations in R&D spending[1][2]. Forest Laboratories is also known for licensing European pharmaceuticals for sale in the United States.

Additional recommended knowledge

One of Forest Laboratories best sellers is the antidepressant Lexapro, which was developed in cooperation with Danish company Lundbeck. Forest also has a drug for the treatment of Alzheimer's disease called Namenda. Namenda has been licensed in Europe for the last 30 years approx. but has only been licensed in the USA in the last two. Both Lexapro and Namenda are produced in bulk at the Forest plant in Dublin, Ireland, with secondary processing such as bottling and blistering being carried out in the USA at plants in New York and St. Louis. Other products include Benicar and Campral. Benicar is used in the treatment of hypertension. Campral is for the maintenance of abstinence from alcohol in patients with alcohol dependence. Other products include Tiazac, Armour Thyroid, Levothroid, Thyrolar, Cervidil, Infasurf, Combunox, and Aerobid.

Forest Laboratories is listed on the New York Stock Exchange under FRX.

It should not be confused with the Forest Products Laboratory.

 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Forest_Laboratories". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE